Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel
NYSE:ANRO

Alto Neuroscience Q2 2026 Earnings Report

Alto Neuroscience logo
$35.03 -0.35 (-0.99%)
As of 09/1/2026 03:58 PM Eastern
ProfileEarnings HistoryForecast

Alto Neuroscience EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.73
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Alto Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alto Neuroscience Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Alto Neuroscience's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Alto Neuroscience's Q2 2026 Press ReleasePress Release
(8-K)
Alto Neuroscience's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Alto Neuroscience Earnings Headlines

Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997888
Alto Neuroscience (NYSE:ANRO) Upgraded by Wall Street Zen to Hold Rating
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989220
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
September 2 at 1:00 AM  |  Stansberry Research (Ad)
Alto Neuroscience Promotes Smith to President, CFO
August 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alto-neuroscience-promotes-smith-to-president-cfo?utm_source=marketbeat.com&utm_medium=referral
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
August 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260827617881/en/alto-neuroscience-promotes-nick-smith-to-president-and-chief-financial-officer/
Alto Neuroscience (NYSE:ANRO) Reaches New 12-Month High - Time to Buy?
August 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30982087
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.

View Alto Neuroscience Profile
Earnings Tools